1355 related articles for article (PubMed ID: 17296539)
1. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
3. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
6. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
7. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
[TBL] [Abstract][Full Text] [Related]
8. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
9. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Chen JJ; Wilkinson JR
J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
11. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
13. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Chen JJ; Ly AV
Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
[TBL] [Abstract][Full Text] [Related]
14. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Youdim MB; Maruyama W; Naoi M
Drugs Today (Barc); 2005 Jun; 41(6):369-91. PubMed ID: 16110345
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline: a review of its use in the management of Parkinson's disease.
Oldfield V; Keating GM; Perry CM
Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
[TBL] [Abstract][Full Text] [Related]
16. Rasagiline. Teva Pharmaceutical.
Kupsch A
Curr Opin Investig Drugs; 2002 May; 3(5):794-7. PubMed ID: 12090555
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
[TBL] [Abstract][Full Text] [Related]
18. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
Bar-Am O; Weinreb O; Amit T; Youdim MB
J Neurochem; 2010 Mar; 112(5):1131-7. PubMed ID: 20002521
[TBL] [Abstract][Full Text] [Related]
19. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
20. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Youdim MB; Gross A; Finberg JP
Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]